Skip Nav Destination
Close Modal
1-20 of 1775 Search Results for
product
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
1
Journal Article
J Health Polit Policy Law (2014) 39 (4): 751–780.
Published: 01 August 2014
... and the economy, the FDA and other executive agencies receive input from the executive branch, the public, and in some cases, the courts, during the process of rulemaking. In this article, we examine the life cycle of FDA regulations concerning medical products and review notable features of the rulemaking...
FIGURES
Image
in Medicaid and Accelerated Approval: Spending on Drugs with and without Proven Clinical Benefits
> Journal of Health Politics, Policy and Law
Published: 01 December 2022
Figure 1 Annual gross and net Medicaid spending by product category. Panel A Gross spending. Panel B Net spending. Notes : Gross spending represents the national total amount reimbursed in the state drug utilization data. Net spending reduces the total to account for Medicaid rebates paid
More
Image
in Medicaid and Accelerated Approval: Spending on Drugs with and without Proven Clinical Benefits
> Journal of Health Politics, Policy and Law
Published: 01 December 2022
Figure 1 Annual gross and net Medicaid spending by product category. Panel A Gross spending. Panel B Net spending. Notes : Gross spending represents the national total amount reimbursed in the state drug utilization data. Net spending reduces the total to account for Medicaid rebates paid
More
Image
in Medicaid and Accelerated Approval: Spending on Drugs with and without Proven Clinical Benefits
> Journal of Health Politics, Policy and Law
Published: 01 December 2022
Figure 2 Proportion of annual Medicaid spending on converted products by product category. Notes : The graph represents the proportion of spending on converted products accounted for by those that completed postapproval confirmatory trials based on surrogate endpoints alone or on clinical
More
Journal Article
J Health Polit Policy Law (1980) 5 (3): 470–497.
Published: 01 June 1980
... at a high level of quality and productivity. Moreover, the gap between the physician/NHP substitution ratio and the NHP/physician cost ratio seems wide enough to assure cost savings when NHPs are used well. Copyright © 1980 by the Dept. of Health Administration, Duke University 1980 New Health...
Journal Article
J Health Polit Policy Law (2017) 42 (4): 645–666.
Published: 01 August 2017
... and credibility of the evidence presented by both supporters and opponents of regulation. It also describes the final deeming rule, published in May 2016, and the FDA's response to the evidence submitted. This is the first study to examine public comments submitted to the FDA's Center for Tobacco Products...
Journal Article
J Health Polit Policy Law (1986) 11 (3): 367–392.
Published: 01 June 1986
... of promotion of tobacco products. The proposal raises complex issues, ranging from determination of the effects of tobacco promotion to assessment of the constitutionality of banning advertising of a legal product. We identify the issues that underlie the concern of health professionals, review evidence...
Journal Article
J Health Polit Policy Law (2009) 34 (6): 863–898.
Published: 01 December 2009
.... Federalism and Technological Change
in Blood Products
Mark Zachary Taylor
Georgia Institute of Technology
Abstract Recent research has shown how federalism affects...
Journal Article
J Health Polit Policy Law (2009) 34 (6): 1035–1077.
Published: 01 December 2009
...Stephen D. Sugarman This article offers a bold new idea for confronting the staggering level of death, injury, and disease caused by five consumer products: cigarettes, alcohol, guns, junk food, and motor vehicles. Business leaders try to frame these negative outcomes as “collateral damage...
Journal Article
J Health Polit Policy Law (2002) 27 (5): 860–862.
Published: 01 October 2002
...Daniel M. Fox David M. Cutler and Ernst R. Berndt, eds. Medical Care Output and Productivity. NBER Studies in Income and Wealth, volume 62. Chicago:University of Chicago Press, 2001. 611 pp. $80.00 cloth. © 2002 by Duke University Press 2002...
Image
in Disinvestments in Practice: Overcoming Resistance to Change Through a Sociotechnical Approach with Local Stakeholders
> Journal of Health Politics, Policy and Law
Published: 01 December 2013
Figure 6 Production Function: Health Benefits to the Population with Eating Disorders at Different Levels of Expenditure Note: The seven “triangles” correspond to the seven assessed services in order of their value-formoney (starting fromthe origin of the graph) (1) university eating disorder
More
Image
in Disinvestments in Practice: Overcoming Resistance to Change Through a Sociotechnical Approach with Local Stakeholders
> Journal of Health Politics, Policy and Law
Published: 01 December 2013
Figure 7 Estimated Production Function Following the Potential Resource Reallocation Detailed in Table 3
More
Image
in Substantial Equivalence Standards in Tobacco Governance: Statutory Clarity and Regulatory Precedent for the FSPTCA
> Journal of Health Politics, Policy and Law
Published: 01 August 2017
Figure 1 Pathways for Introduction of Novel or Altered Products under the FSPTCA Note : For products claiming modified or reduced risk, a separate pathway exists under section 911.
More
Image
in Informed or Misinformed Consent? Abortion Policy in the United States
> Journal of Health Politics, Policy and Law
Published: 01 April 2016
Figure A2 Map of States with Mandated Production of Written Informed Consent Materials Notes : Dark gray states mandate the production of informed consent materials. States coded in light gray (IN, MS) did not have materials available at the time of this study.
More
Journal Article
J Health Polit Policy Law (2017) 42 (4): 607–644.
Published: 01 August 2017
...Figure 1 Pathways for Introduction of Novel or Altered Products under the FSPTCA Note : For products claiming modified or reduced risk, a separate pathway exists under section 911. ...
FIGURES
Image
in The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies
> Journal of Health Politics, Policy and Law
Published: 01 December 2022
Figure 1 Aggregate growth in rebates, list prices, and net prices (2009-2019). Panel A Annual rebate growth. Panel B List and net price inflation. Notes : Both panels reflect analysis of 1,374 branded product formulations sold in primarily retail pharmacies, but the sample varies in each
More
Image
in The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies
> Journal of Health Politics, Policy and Law
Published: 01 December 2022
Figure 1 Aggregate growth in rebates, list prices, and net prices (2009-2019). Panel A Annual rebate growth. Panel B List and net price inflation. Notes : Both panels reflect analysis of 1,374 branded product formulations sold in primarily retail pharmacies, but the sample varies in each
More
Journal Article
J Health Polit Policy Law (2017) 42 (6): 1099–1112.
Published: 01 December 2017
... versus tobacco/nicotine harm reduction for minors. Protecting youth from tobacco is critical, especially since tobacco/nicotine products are legal for adults, who usually begin using when young. Although cigarettes and other combustibles are the deadliest tobacco products, other products...
Journal Article
J Health Polit Policy Law (2002) 27 (6): 977–1000.
Published: 01 December 2002
...Ann Boulis; Susan Goold; Peter A. Ubel In fall 1997, a shortage of intravenous immunoglobulin (IVIG) developed in the United States because of increased demand for the product, reduced supply,and product recalls. This shortage is a useful model for understanding how our health care system responds...
Journal Article
J Health Polit Policy Law (2022) 47 (6): 629–648.
Published: 01 December 2022
...Figure 1 Aggregate growth in rebates, list prices, and net prices (2009-2019). Panel A Annual rebate growth. Panel B List and net price inflation. Notes : Both panels reflect analysis of 1,374 branded product formulations sold in primarily retail pharmacies, but the sample varies in each...
FIGURES
| View All (4)
Includes: Supplementary data
1
